Portman Square Capital LLP Alnylam Pharmaceuticals, Inc. Transaction History
Portman Square Capital LLP
- $2.72 Billion
- Q2 2024
A detailed history of Portman Square Capital LLP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Portman Square Capital LLP holds 11,848 shares of ALNY stock, worth $3.18 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
11,848
Previous 56,300
78.96%
Holding current value
$3.18 Million
Previous $8.41 Million
65.78%
% of portfolio
0.11%
Previous 0.26%
Shares
6 transactions
Others Institutions Holding ALNY
# of Institutions
614Shares Held
108MCall Options Held
2.33MPut Options Held
2.17M-
Capital World Investors Los Angeles, CA15MShares$4.01 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.35 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.56 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.66 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.62 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...